1. Discuss the potential role of adjuvant treatment with immune checkpoint inhibitors in renal cell carcinoma
  2. Identify the use of radioligands in the treatment of metastatic prostate cancer
  3. Apply expanding landscape of targetable alterations and novel targeted therapies in metastatic NSCLC to clinical practice
  4. Explain new advances in adjuvant/neoadjuvant therapy in early-stage NSCLC

This session will be VIRTUAL ONLY. This means the lecture hall will NOT be open.

Zoom info:

Join from a PC, Mac, iPad, iPhone or Android device:

    Please click this URL to join. https://uwmadison.zoom.us/s/96952453000?pwd=UWhtQStlMnlvTEFyckZzTXQ4QzZidz09

    Passcode: UWCCC

                Description: Presenters, please use the link that zoom sends you and don't forward to anyone else. Thank you!

Or One tap mobile:

    +19292056099,,96952453000# US (New York)

    +13017158592,,96952453000# US (Washington DC)

Or join by phone:

    Dial(for higher quality, dial a number based on your current location):

        US: +1 929 205 6099  or +1 301 715 8592  or +1 312 626 6799  or +1 669 900 6833  or +1 253 215 8782  or +1 346 248 7799

    Webinar ID: 969 5245 3000

    International numbers available: https://uwmadison.zoom.us/u/ad7M1m0CiT

Session date: 
Wednesday, September 15, 2021 - 8:00am to 9:00am
Location: 
Health Sciences Learning Center, #1306 Lecture Hall
600 Highland Ave
Madison, WI 53792
United States
  • 1.00 ACPE Contact Hours - Pharmacist
  • 1.00 AMA PRA Category 1 Credit
  • 1.00 ANCC Contact Hours
  • 1.00 University of Wisconsin–Madison Continuing Education Hours
    • 1.00 Approved for AMA PRA Category 1 Credit™

Please login or register to take this course.
Discloser List CME Internal Report
Presenter(s): 
Dr. Hamid Emamekhoo
Dr. Nan Sethakorn